PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levomenol→

Levomenol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
23089-26-1
Molecular formula
C15H26O
Molecular weight
222.37 g/mol
Drug class
Topical bisabolol sesquiterpene alcoholskin-conditioning and anti-inflammatory agent
Mechanism of action
Levomenol (alpha-bisabolol) is a naturally occurring sesquiterpene alcohol with reported local anti-inflammatory, soothing and skin-conditioning properties. Proposed activities include modulation of inflammatory mediator release and enhancement of skin-barrier recovery.
Indications / reported uses
  • Used as a topical skin-conditioning and soothing ingredient in dermatological and cosmetic preparations; clinical indications depend on the specific product and formulation. It is not a systemic therapeutic API.

Sources: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=levomenol&lang=eng · https://pubchem.ncbi.nlm.nih.gov/#query=levomenol · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Levomenol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levomenol Permitted Daily Exposure (PDE) report (the Levomenol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levomenol Occupational Exposure Limit (OEL) report (the Levomenol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.